New Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes
18 Maio 2023 - 9:00AM
Daxor Corporation (Nasdaq: DXR),
the global leader in blood volume measurement technology, today
announces new data demonstrating the importance and clinical
utility of Daxor’s BVA-100 blood test in heart failure patients
published in the European Society of Cardiology Heart Failure. The
results of the study demonstrated Daxor’s blood volume analysis
(BVA) provides unique and individualized data that is critical for
targeting heart failure therapy and is predictive of clinical
outcomes.
The study titled, “Differences in Red Blood Cell
Mass Profiles Impact Intravascular Volume and Outcome Risk in
Chronic Heart Failure,” studied the differences in total blood
volume and red blood cell mass – two critical treatment targets in
patients who were considered clinically stable and their impact on
clinical outcomes in chronic heart failure. Both measures were
determined using Daxor’s innovative BVA technology. The results
showed that survival rates of patients could be predicted with
blood volume analysis via Daxor’s test from their red blood cell
levels.
Wayne L. Miller, M.D., Department of
Cardiovascular Disease, Mayo Clinic, Rochester, MN, lead author of
the study, concluded, “The findings of this study demonstrate that
patients with chronic heart failure develop marked differences in
profiles despite comparable stable clinical status, and that this
variability has significant associations with the important
clinical outcomes of heart failure-related mortality and
hospitalizations.”
“Our test uniquely informs clinicians with two
important treatment targets to help individualize and treat volume
derangements in complex heart failure patients,” said Michael
Feldschuh, CEO of Daxor Corporation. “Past studies in peer-reviewed
journals have shown substantial improvements in mortality
reduction, hospital readmission, and costs from the use of our
diagnostic.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing multicenter trials in
the areas of COVID-19 and heart failure treatment with support from
the NIH and is under contract developing analyzers to improve
combat casualty care with the U.S. Department of Defense. Daxor's
mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr. Managing Partner,
CORE IR516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024